GlaxoSmithKline , WHO-TDR and the Medicines For Malaria Venture collaborate to fight malaria
Auckland, April 29, 2004 - GlaxoSmithKline (GSK), the World Health Organisation's Special Programme for Research and
Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria Venture (MMV) today announced the signing of a
collaborative agreement, to develop a new-fixed dose artemisinin combination therapy drug (ACT), combining
chlorproguanil, dapsone and artesunate (CDA) for the treatment of malaria.
In Africa, the malaria crisis is escalating mainly due to multi-drug resistance. The most frequently used treatments
for malaria, such as chloroquine and sulfadoxine/ pyrimethamine (SP), are becoming less and less effective. To tackle
drug resistant malaria, new treatments are urgently needed to provide effective therapy to the millions in need. The
development of CDA responds to the World Health Organisation's 'Roll Back Malaria' recommendations for the National
Malaria Control Programmes (NMCP) to use artemisinin based combination therapy as the preferred treatment of
uncomplicated falciparum malaria.
"Partnership is essential to combine resources and expertise; and accelerate the process of providing safe, effective
and affordable drugs. It is the best way to help ensure that a drug such as CDA gets to the people in need as quickly as
possible", explained Chris Hentschel, CEO, MMV.
"WHO-TDR has already collaborated with GSK and other partners to successfully develop an antimalarial and we believe
that developing a drug combining chlorproguanil, dapsone, and artesunate will enhance clinical efficacy in malaria
treatment and also delay the development of resistance by the malaria parasites." said Robert Ridley, Acting Director,
WHO-TDR.
"GSK is committed to participating in public-private partnerships such as this one for CDA, and to bringing urgently
needed medicines to people in the developing world faster," said Dr Ian Griffiths, Medical Director, GlaxoSmithKline New
Zealand.
This new CDA development project is based on the development of dapsone and chlorproguanil supported by an initial
grant from the UK Department of International Development (DFID). The development team is chaired by Professor Peter
Winstanley of the University of Liverpool, one of the academic partners involved in the development of the drug, along
with the Liverpool School of Tropical Medicine and the London School of Hygiene & Tropical Medicine.
The agreement states that if the development of CDA is successful as a result of this initiative, it will be made
available at preferential prices to the public sector in malaria endemic countries, so as to maximize its availability
to those in need. If targets are met the drug should be ready for regulatory submission in 2006.
"This new treatment could be an important development in the fight against malaria", said Dr F Nafo-Traoré, Director of
the Roll Back Malaria department, WHO. "We hope that it will prove useful in regions of Africa where resistance makes
older antimalarials ineffective."
The World Health Organisation estimates that there are 300 - 500 million malaria cases annually, directly causing 1
million deaths and directly contributing to a further 1.7 million deathsi. It is the leading cause of death in young
children in Africa. Hundreds of millions of African children and adults are chronically infected with malaria. Between
30 and 50% of inpatient admissions and 50% of outpatient visits are attributed to malaria each yearii. Beyond the human
toll, malaria has significant economic impacts in the endemic countries - costing Africa $12 billion in lost GDP every
year and consuming 40 percent of all public health spending.
Notes to Editors:
About MMV
Medicine for Malaria Venture was officially launched on 3 November 1999 as a non-profit foundation dedicated to reducing
the burden of malaria in disease endemic countries by discovering, developing and delivering new affordable
antimalarials through effective public-private partnership. After four years of operation, MMV is managing the largest
portfolio of malaria research in history with 21 Projects in different stages of drug research and development. For
further information please consult http://www.mmv.org.
About GSK
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to
improving the quality of human life by enabling people to do more, feel better and live longer. For company information,
visit GlaxoSmithKline on the World Wide Web at www.gsk.co ,nz
About WHO/TDR
The Special Programme for Research and Training in Tropical Diseases (TDR) is a special programme co-sponsored by UNDP,
WHO, UNICEF and the World Bank. It helps to coordinate, support and influence global efforts to combat a portfolio of
major diseases of the poor and disadvantaged. TDR acts as a 'global facilitator' of research and training, providing
guidance and grants for research priorities and opportunities in its targeted 10 neglected diseases.
i World Health Organisation, RBM Infosheet 1 of 11, March 2002
ii World Health Organisation, RBM Infosheet 1 of 11, March 2002